Cell motility drives many biological processes, including immune responses and embryonic development. In the brain, microglia are immune cells that survey and scavenge brain tissue using elaborate and motile cell processes. The motility of these processes is guided by the local release of chemoattractants. However, most microglial processes retract during prolonged brain injury or disease. This hallmark of brain inflammation remains unexplained. We identified a molecular pathway in mouse and human microglia that converted ATP-driven process extension into process retraction during inflammation. This chemotactic reversal was driven by upregulation of the A 2A adenosine receptor coincident with P2Y 12 downregulation. Thus, A 2A receptor stimulation by adenosine, a breakdown product of extracellular ATP, caused activated microglia to assume their characteristic amoeboid morphology during brain inflammation. Our results indicate that purine nucleotides provide an opportunity for contextdependent shifts in receptor signaling. Thus, we reveal an unexpected chemotactic switch that generates a hallmark feature of CNS inflammation.
Brain inflammation is thought to be driven primarily by microglia, the resident hematopoietic cells of the brain and the first responders to most types of CNS insults. Disturbances in brain homeostasis trigger a rapid response by microglia, which have been termed the 'pathology sensors' of the CNS 1,2 . Under normal in vivo conditions, microglia have highly branched and motile cell processes that undergo continuous structural remodeling [3] [4] [5] . Within minutes of brain damage, these processes rapidly extend toward newly injured areas to shield and/or scavenge the affected site 3, 4 . This chemoattractive response toward sites of CNS injury is triggered partly by the release of ATP and/or ADP from affected tissue and the consequent activation of the purinergic P2Y 12 receptor on microglia 5 .
In contrast with their ramified morphology under normal conditions, chronic brain damage and neurodegeneration are typically accompanied by microglia with an amoeboid morphology and highly retracted processes 1,2,6,7 . Although microglial process retraction has been documented for over 80 years 8 and serves as a defining feature of brain inflammation, its causes and consequences remain unknown. Notably, P2Y 12 is rapidly downregulated in activated (that is, proinflammatory) microglia, and this decline in P2Y 12 expression correlates with the retraction of microglial processes and the adoption of the amoeboid morphology 5 . However, the basis for this relationship and the triggers of microglial process retraction have not yet been revealed. It also remains unknown whether activated microglia, without expression of P2Y 12 , show any chemotactic response to ATP and/or ADP that is released during injury. Given that most neuropathologies are characterized by ongoing neuronal injury in the presence of activated microglia, examination of ATP responses by activated microglia may reveal new information about microglial function during neuroinflammation. Here, we investigated the chemotactic and morphological responses by microglia to ATP under both resting and activated states.
RESULTS

Chemotactic and morphological effects of ATP
We first examined whether untreated and activated microglia migrate differently in the presence of ATP, a known microglial chemoattractant that is released from injured cells 4, 5, 9, 10 . To activate microglia, we pretreated cells cultured in a three-dimensional matrix with the pattern-recognition receptor agonist lipopolysaccharide (LPS), which activates toll-like receptor 4 (TLR4) and is known to mimic both pathogenic and nonpathogenic immune responses 7 , for 24 h (Fig. 1) . We then created an ATP gradient by locally applying ATP onto control or LPS-activated microglia using iontophoresis and assessed chemotaxis toward the point source of ATP by carrying out time-lapse threedimensional confocal imaging. As expected, localized ATP exposure triggered asymmetric process extension and migration of untreated microglia toward the iontophoretic pipette tip (Fig. 2a-c) . Notably, LPS-treated microglia showed asymmetric retraction of processes and repulsive migration away from the pipette (Fig. 2d-f and Supplementary Video 1 online). These results indicate that, although ATP acts as an attractant for untreated microglia, it acts as a repellant for LPStreated microglia.
To better understand the intracellular mechanisms driving these opposing chemotactic responses by microglia, we carried out timelapse three-dimensional imaging during bath application of agonist. This method enabled us to quantify changes in microglial cell structure and motile responses by individual cell processes without interference from cell migration, as no agonist gradient existed in the recording chamber under these conditions (Fig. 3a-f and Supplementary Fig. 1  online) . In control microglia, we observed that global ATP exposure triggered a rapid and reversible increase in microglial surface area-tovolume ratio ( Fig. 3g and Supplementary Video 2 online), reflecting cell process extension. Moreover, tracking individual cell processes revealed that ATP also increased the velocity of process movement, which we interpreted as increased microglial process motility (Fig. 3h) . These four-dimensional analyses in control microglia support previous findings that ATP serves as a chemoattractant for resting cells 4, 5, 9, 10 .
In addition to LPS, we also examined microglia activated with agonists of other pattern recognition receptors, including lipoteichoic acid (LTA, activator of TLR2) and unmethylated CpG motifcontaining oligonucleotides (CpG, activator of TLR9). We also examined microglia activated with tumor necrosis factor a (TNF-a), a proinflammatory cytokine released during most types of brain injuries 11 . Instead of process extension, activated microglia showed symmetric process retraction on bath application of ATP. Specifically, ATP triggered a decrease in both the surface area-to-volume ratio and process velocity, reflecting process withdrawal and slowed motility (Fig. 3g-h and Supplementary Videos 3 and 4 online). This shift in response required a long time period (412 h), suggesting that changes in protein expression were necessary (Fig. 3i) . Consistent with this, blockade of nuclear factor-kB (NF-kB), a transcription factor involved in microglial activation, during pre-treatment prevented retraction and low motility after ATP exposure (Fig. 3j-k) . Complement 5a (C5a), another chemoattractant for microglia 12 , continued to elicit process extension in LPS-activated microglia (Fig. 3l) , suggesting that the shift to repulsion is specific to purinergic stimulation.
Upregulation of the G s -coupled A 2A receptor We next addressed the receptor signaling mechanisms driving this effect in activated microglia. It is known that resting microglia are attracted to ATP or acute injury at least partly as a result of Rac GTPase-driven actin polymerization downstream of the G i -coupled P2Y 12 receptor 3,4,9,10 . However, P2Y 12 is rapidly downregulated following microglial activation 5, 13 ( Supplementary Fig. 2 online), suggesting that a different receptor system may mediate chemotactic injury responses by activated microglia. Although the signaling mechanisms driving microglial retraction are unknown, other cell types undergo retraction as a result of remodeling of the actin cytoskeleton, which often involves G 12/13 -coupled activation of Rho GTPase and Rho kinase (ROCK) 14, 15 . Staining the microglial actin cytoskeleton suggested that actin remodeling participates in microglial repulsion ( Supplementary  Fig. 3 online) . However, inhibition of either Rho GTPase or ROCK did not attenuate microglial repulsion (Fig. 4) , indicating that an alternative mechanism may drive this response. Notably, G s -coupled signaling can suppress motility in select cell types 16, 17 . This pathway involves activation of adenylate cyclase, which produces cyclic AMP (cAMP) β-actin RT-PCR analysis in cultured mouse microglia indicates that control microglia (C) had low mRNA levels for known proinflammatory factors, as indicated. Following LPS treatment (100 ng ml -1 , 24 h), microglia showed robust upregulation of these factors (n ¼ 3). COX-2, cyclooxygenase-2; IL-1b, interleukin-1b; iNOS, inducible nitric oxide synthase; MMP-9, matrix metalloproteinase-9; MCP-1, monocyte chemoattractant protein-1. and thereby activates protein kinase A (PKA). We therefore tested whether ATP regulates microglial motility via G s -coupled signaling. Indeed, inhibition of Ga s or factors downstream of Ga s , including adenylate cyclase or PKA, attenuated ATP-induced retraction and slowed motility in activated microglia (Fig. 4a-e and Supplementary  Fig. 3 ). Conversely, stimulating adenylate cyclase with forskolin induced dose-dependent retraction in both control and activated microglia (Fig. 4f) . Moreover, constitutive activation of Ga s with cholera toxin blunted membrane extension in nonstimulated cells and induced microglial cell rounding in 24 h (data not shown). These results indicate that G s signaling is necessary and sufficient for microglial repulsion.
Together, our data implicate a G s -coupled receptor in the chemorepulsion of activated microglia by ATP. However, there is no known G s -coupled mouse P2Y receptor. Therefore, we considered other receptor classes. When it is released in the brain, ATP is rapidly broken down to adenosine by extracellular and membrane-bound nucleotidases, including CD39 and CD73 (ref. 18 ). We investigated the role of adenosine receptors, two of which (A 2A and A 2B ) are G s coupled 19 . Reverse transcription PCR (RT-PCR) revealed that, although P2Y 12 was lost, the high-affinity adenosine receptor A 2A was selectively upregulated following microglial activation with TLR agonists or with TNF-a (Fig. 5a) . Indeed, A 2A mRNA upregulation has been observed previously in microglia treated with LPS, but has not been functionally studied 20 . Notably, aggregated amyloid-b (Ab), a main component of extracellular amyloid plaques in Alzheimer's disease, also triggered microglial A 2A upregulation and P2Y 12 downregulation (Fig. 5a) . Consistent with the idea that A 2A has a functional role in repulsion, we found that both 5¢-(N-ethylcarboxamido)adenosine (NECA), a nonselective adenosine receptor agonist, and CGS-21680, an A 2A -selective agonist 18, 19 , mimicked ATP by triggering retraction in activated microglia, but the agonists had little effect on nonstimulated microglia ( Fig. 5b and data not shown) . Moreover, the A 2A -selective antagonist SCH-58261 (refs. 18,19) attenuated microglial repulsion from ATP (Fig. 5c) , further suggesting that A 2A mediates repulsion. Although ATP does not activate the A 2A receptor directly, it is rapidly hydrolyzed into adenosine, which is a potent activator of the A 2A receptor ( Supplementary Fig. 4 online) 18 . Reasoning that ATP degradation into adenosine is a necessary step leading to microglial repulsion, we stimulated cells with ATP in the presence of adenosine deaminase (ADA), which converts adenosine into inosine. Consistent with our working hypothesis, ADA inhibited retractile responses (Fig. 5c) , demonstrating that ATP-induced microglial repulsion is mediated by the ATP breakdown product adenosine.
A 2A receptor upregulation has also been reported in human macrophages and in brain tissue from individuals with Alzheimer's disease 21, 22 . We investigated whether adult human microglia also upregulate A 2A expression after inflammation-driven activation and consequently show chemotactic reversal in response to ATP. We observed that LPS-activated adult human microglia had marked A 2A upregulation along with a loss of P2Y 12 expression (Fig. 6a) . Notably, although nonstimulated human microglia showed migration toward and engulfment of an ATP-filled pipette, LPS-stimulated human microglia showed repulsion (Fig. 6b and Supplementary Videos 5 and 6 online). Thus, a similar chemotactic switch takes place in adult human microglia. (Fig. 7a) . Next, we used transgenic Cx3cr1-eGFP mice, which show microglia-specific eGFP labeling 3-5 . Although eGFP was localized exclusively to microglial cells among CNS-resident cellular elements, the fluorescent reporter did not differentiate between resident microglia and infiltrating mononuclear phagocytes, which may have microglial morphology. Following LPS exposure, these mice showed characteristic retracted microglia throughout the brain, a hallmark of activated microglia and induction of CNS inflammation ( Fig. 7b and Supplementary Fig. 5 online) . In these LPS-treated mice, we observed that intracortical injection of the A 2A -specific antagonist SCH-58261 resulted in microglial process re-extension within 30 min, an effect that was not seen in mice injected with vehicle alone (Fig. 7b and Supplementary Fig. 5 ). These observations are consistent with our in vitro data and suggest that activated microglia may assume an amoeboid phenotype in vivo as a result of A 2A receptor stimulation by purine nucleotides released in the brain.
Role of
Previous studies have shown that acute injury results in the release of ATP and other nucleotides from damaged cells, which triggers chemoattraction of microglial processes toward sites of injury 4, 5 . We therefore asked whether acute tissue damage can repel processes of activated microglia. To address this, we carried out time-lapse imaging on eGFP-positive microglia that were cocultured with wild-type astrocytes that received focal injury with a pipette tip. We observed that acute damage triggered adjacent microglia to extend processes toward injury (n ¼ 3; Supplementary Video 7 online). However, following coculture exposure to LPS, damage triggered microglial retraction from the injury site (n ¼ 6; Supplementary Video 8 online), suggesting that the chemotactic response of microglial processes to acute tissue damage may be reversed during inflammation. We also examined whether A 2A -driven process retraction may influence the rate of phagocytosis by cultured microglia. Indeed, we observed a decrease in particle uptake by LPS-treated microglia in the presence of A 2A agonists, including CGS-21680, adenosine and ATP (Fig. 8) , suggesting that A 2A stimulation may modulate substrate engulfment by activated microglia.
DISCUSSION
Activated microglia are known to retract into an amoeboid shape during neurological disease or trauma. The cause and importance of this phenomenon have remained unknown. We found that the microglial chemotactic response to ATP is reversed following microglial activation. This reversal, a switch from process attraction to repulsion, is driven by upregulation of the G s -coupled A 2A receptor coincident with downregulation of the G i -coupled P2Y 12 receptor (see schematic in Supplementary Fig. 6 online) . We further propose that degradation of extracellular ATP to adenosine by ectonucleotidases, such as CD39 and CD73, which are thought to be expressed by microglia [23] [24] [25] [26] , leads to activation of the adenosine A 2A receptor and consequent process retraction by activated microglia. Given that extracellular ATP and its metabolite adenosine are ubiquitous in the brain [27] [28] [29] [30] [31] , our results suggest that activated microglia may assume their characteristic amoeboid morphology as a result of A 2A -driven process repulsion from endogenously produced adenosine.
To the best of our knowledge, this is the first extracellular signaling factor that acts to repel microglial processes, an aspect of neuroimmune responses that requires further study. Moreover, our findings of A 2A agonist effects on microglial phagocytosis suggest that this receptor may affect microglial function beyond process retraction. Thus, additional research into the effects of A 2A receptor stimulation on activated microglia is needed to fully elucidate the roles that this receptor has in microglial activity. We also conclude that G s -coupled intracellular signaling may be an important regulator of microglial function, as has been suggested previously [32] [33] [34] . Further investigation into the effects of G s -coupled signaling in microglia may help to address long-standing and fundamental questions regarding the nature of microglial activation and may reveal new therapeutic strategies for CNS diseases.
Notably, A 2a ablation and A 2A receptor antagonists, including caffeine, are known to modulate brain injury in animal models of CNS trauma and neurodegeneration [35] [36] [37] . However, although neuronal and astrocytic A 2A receptors are thought to be involved in brain injury, the effects of microglial A 2A receptor upregulation during inflammation require further investigation. We and others 20 have shown that microglial A 2A expression is only evident following proinflammatory activation, but some studies have suggested that A 2A may also be expressed by cultured microglia before activation [38] [39] [40] . However, we have not been able to detect microglial A 2A expression in normal Adora2a-eGFP mice or in untreated cultured mouse or human microglia using RT-PCR or time-lapse three-dimensional imaging with A 2A agonists. Thus, the state of microglial activation and the specific pattern of purinergic receptor expression may vary under different culture conditions. In summary, our results suggest that A 2A -dependent repulsion is a major driving force for microglial deramification, a hallmark of neuroinflammation. Our data also reveal a flexible duality in microglial cell motility. We found that microglial motility can switch between chemoattraction and repulsion on the basis of changes in cell surface receptor signaling. These results demonstrate a previously unrecognized adaptive feature of microglial motility that allows ATP to induce an opposite chemotactic response during inflammation. 
METHODS
Methods
ONLINE METHODS
Cell cultures. All procedures were approved by the Institutional Animal Care and Use Committee or the Institutional Review Board of Emory University. Mice expressing eGFP driven by an actin promoter (a gift from M. Okabe, Osaka University) were used to culture microglia. Cortical tissue from postnatal day 2-3 Actb-eGFP or wild-type C57Bl/6 mice (Jackson Laboratory) was dissociated and plated with serum-supplemented DMEM (Gibco catalog 11960) containing 25 mM glucose, 2 mM glutamine and 1 mM sodium pyruvate. After 2-3 weeks, floating microglia were isolated and plated onto Matrigel matrix-coated coverslips (BD Biosciences, thickness B0.2 mm). Microglia adhered overnight and were confirmed to be Z95% pure on the basis of isolectin GS-IB 4 (IB 4 ) staining (data not shown). For astrocytemicroglia cocultures, eGFP-positive microglia were applied onto 50% confluent wild-type astrocytes and allowed to adhere overnight. Human microglia were cultured as previously described 41 . Adult human microglial cells were obtained from two Emory University Hospital patients (ages 30-45) undergoing hippocampectomy as a result of seizures or resection as a result of a subarachnoid tumor. Human microglia were allowed to adhere for 5-7 d before imaging.
Reagents. ATP, ADP, AMP, NECA, adenosine, A2a agonist CGS-21680, A2a antagonist SCH-58261, LPS, LTA from Staphylococcus aureus, Ga s inhibitor NF449 and the PKA inhibitor H89 were all purchased from Sigma. The NF-kB inhibitors QNZ and SN50, forskolin, the adenylate cyclase inhibitor ddAdo, the Ga s activator cholera toxin (Vibrio cholerae), the Rho GTPase inhibitor exoenzyme C3 (Clostridium botulinum), the ROCK inhibitor Y27632, and ADA were all purchased from Calbiochem. We also used recombinant mouse complement component C5a, recombinant mouse TNF-a (R&D Systems) and unmethylated CpG (InvivoGen). IB 4 from Griffonia simplicifolia and human b-amyloid 1-42 (aggregated according to manufacturer instructions) were obtained from Invitrogen.
Four-dimensional confocal imaging. Cells were continuously perfused with imaging buffer 10 mM HEPES, 150 mM NaCl, 3 mM KCl, 22 mM sucrose, 10 mM glucose, 1 mM MgCl 2 and 2 mM CaCl 2 (pH 7.4). The buffer was maintained at 32-33.5 1C using a TC-344B temperature controller (Warner Instruments). After establishing upper and lower z axis limits, time-lapse confocal image stacks of eGFP microglia were acquired every 15-20 s. Each image stack spanned the entire z plane of microglia at 0.5-2-mm steps (25-30 images per stack). Image stacks were acquired using IPlab software (BD Biosciences), an Olympus IX51 microscope with a DSU confocal unit, a MFC-2000 z-motor (ASI) and a Uniblitz shutter (Vincent Associates). Image stacks were collected continuously during 5-min periods of buffer perfusion, agonist perfusion and washout with an ORCA-ER-cooled CCD camera (Hamamatsu).
Image processing and analysis. Following acquisition, images were compiled and transformed into four-dimensional renderings of microglia throughout the course of a perfusion using Imaris 4.2 (Bitplane). After background-noise subtraction with a 10-mm-wide Gaussian filter, image stacks were reconstructed into three-dimensional surfaces at each time-point on the basis of calibrated voxel sizes (xy, 0.105 mm 2 ; z, 0.5-2 mm), a signal intensity threshold and a 0.2-mm-wide Gaussian filter. All time-lapse surfaces were then split into objects to enable measurements of cell volume and surface area through time. Cell surface area-to-volume ratio at each time point was then calculated to assess changes in cell structure. Microglial cell process motility was assessed by comparing the average speed of tracked regions of interest (ROIs) in cell processes during periods of buffer and agonist perfusion. ROIs, or discrete spherical volumes of fluorescence, were analyzed on the basis of predefined criteria, such as minimum diameter, maximum travel distance between consecutive image stacks and the type of tracking algorithm used. To assign ROIs to cell processes and enable tracking, we first optimized these criteria. While we varied these parameter values, we compared the sensitivity and reliability of the tracking analysis to agonistinduced changes in track speed, number of tracks and track length (Supplementary Fig. 1, and data not shown) . In addition, we minimized changes in the number of unassigned ROIs (that is, regions not designated by the algorithm to any track). As determined empirically, the parameter values that we held constant for all analyses of process motility were a minimum diameter of 2 mm, a maximum travel distance of 3 mm and we used the GapClose Autoregressive tracking algorithm, a function that matches predicted ROI positions with actual ROI positions in image data and thereby models continuous motion. Tracks created in the cell body were omitted from analyses. Baseline process ramification of the control group was lower than that of CpGand TNF-a-treated groups (P o 0.01), but not different from LPS-and LTAtreated groups. Baseline process motility of the control group was lower than that of CpG-and LPS-treated groups (P o 0.01), but not different from LTA-and TNF-a-treated groups.
Iontophoresis. A glass micropipette (inner diameter, 1.15 ± 0.05 mm; outer diameter, 1.65 ± 0.05 mm; glass type 8250, Garner Glass) was pulled to a B1.4-MO tip with a Narishige pipette puller, filled with agonist diluted in imaging buffer and attached to a micromanipulator and a current generator (Model 6400, Dagan). The positive holding current value (+80 nA) was determined empirically by observing microglial morphological responses (occurrence of membrane ruffling) while in close proximity to an ATPcontaining micropipette with different holding currents. Agonist application was performed by ejecting a -200-nA current. To analyze cell chemotaxis in response to iontophoretic agonist application, we tracked cell body by setting the ROI diameter to the size of the nucleus.
Actin filament staining. Cultured wild-type microglia were treated with agonists, fixed and stained with 1:100 Alexa Fluor 488 phalloidin (Invitrogen) and 1:100 IB 4 to identify microglia.
In vivo injections and immunohistochemistry. Transgenic mice that encode eGFP in place of exon 2 in the Cx3cr1 gene were obtained from the Jackson Laboratory. Mice (1-3 months old) received a single intraperitoneal injection of either sterile phosphate-buffered saline (PBS) or LPS (2 mg per kg, 100 ml total volume). After 48 h, mice were anesthetized with Avertin and placed into a stereotaxic apparatus for an intracortical injection of vehicle (50% DMSO (vol/vol) in PBS, 2 ml) or the A2A antagonist SCH-58261 (1 mM in 2 ml) at 400 nl per min at 1.0 mm caudal, 2.0 mm lateral and 1.0 mm ventral from bregma. The needle was left in place for 5 min. After another 25 min, brain tissue was removed, drop-fixed overnight in 4% paraformaldehyde (wt/vol) with 0.1% glutaraldehyde (vol/vol) and cryopreserved in sucrose. We washed 40-mm-thick sections in PBS and placed them on slides for microscopy. Adora2a-eGFP BAC transgenic mice were obtained from the Mutant Mouse Regional Resource Centers and received an intraperitoneal injection of either sterile PBS or LPS (2 mg per kg, 100 ml total volume). After 48-72 h, tissue was processed and immunostained using an antibody to GFP (1:1,000, Invitrogen).
RT-PCR. Total RNA was derived from homogenized primary mouse microglia using the Purelink Micro-to-Midi total RNA purification system (Invitrogen) according to the manufacturer's instructions. RNA (50 ng) was then reverse transcribed and amplified using the SuperScript III One-Step RT-PCR System with Platinum Taq (Invitrogen) and specific primers, as detailed previously 5, [42] [43] [44] [45] [46] [47] [48] [49] [50] . cDNA synthesis was carried out at 50 1C for 30 min, followed by pre-denaturation at 94 1C for 2 min, 30-40 cycles of denaturation at 94 1C for 15 s, annealing at 55 1C for 30 s (except for P2Y4: 51 1C; hP1 receptors: 58 1C; activation markers: 60 1C) and finally by elongation at 70 1C for 1 min. To check for DNA contamination, we omitted reverse transcriptase from some reaction mixtures. For primer pairs that did not produce visible bands using isolated RNA, 2 ng of cDNA encoding each receptor was used to run control reactions. Plasmids for mouse adenosine receptors and mP2Y2 were from obtained Open Biosystems and mP2Y4 and mP2Y6 were a gift from W. O'Neal (University of North Carolina, Chapel Hill).
Uptake assay. Microglial phagocytosis was analyzed using the Vybrant phagocytosis assay kit (Invitrogen) according to the manufacturer's instructions. Briefly, primary mouse microglia were isolated, allowed to adhere overnight onto 0.05 mg ml À1 poly-D-lysine-coated 96-well plates and treated with LPS (100 ng ml À1 ) at 37 1C for 24 h. After pre-exposure to ATP (50 mM), CGS-21680 (50 mM) or adenosine (50 mM) for 20 min, fluorescein-labeled Escherichia coli bioparticles were applied for 2 h along with agonists. Cells were examined using the FlexStation II microplate reader (Molecular Devices) at 480-nm excitation and 520-nm emission. Results were normalized to empty wells and DMEM-treated cells.
cAMP assay. Agonist-induced release of cAMP was measured using the CatchPoint Cyclic-AMP Fluorescence Assay kit (Molecular Devices) with some modification to the manufacturer's instructions. Briefly, HEK293 cells were plated with DMEM-Glutamax supplemented with 10% fetal bovine serum (vol/vol), 10 U ml À1 penicillin and 10 mg ml À1 streptomycin, and transfected with cDNA encoding the mouse A 2A receptor (Open Biosystems) at a 3:1 ratio using FuGene 6 (Roche). HEK cells were then incubated in 0.75 mM 3-isobutyl-1-methylxanthine (Sigma) for 10 min to inhibit phosphodiesterase activity. Indicated agonists or 30 mM forskolin (activator of adenylate cyclase) were then added for 15 min at 37 1C. The fluorescence intensity in each well was detected using the FlexStation II plate reader (Molecular Devices) using 530-nm excitation and 590-nm emission.
Statistics. All statistical tests were performed on the raw data except for the phagocytosis analysis. Average cell ramification, process track speed and migration during baseline were compared with periods of agonist exposure using a paired Student's t test. Data were normally distributed and had equal variances, as verified using Bartlett's test. Analyses of different pretreatment conditions or inhibitor effects on agonist responses in the confocal imaging experiments were performed using repeated-measures two-way ANOVA. cAMP release was analyzed with one-way ANOVA and Dunn's multiple comparisons post-test. Phagocytosis analysis was performed with the Kruskal-Wallis test and Dunn's multiple comparisons post-test.
